Finally, we examined the cumulative effect of the HLA-A and-E polymorphism on the risk of EBV-positive cHL through the comparison of protective phenotypes (E*01:01+ve, A*01-ve or/and A*02+ve) to all other phenotypes or to its opposite risk phenotype (E*01:01-ve, A*01+ve or/and A*02-ve) (Table 5). The gene discussed is HLA-A; the disease is classic Hodgkin lymphoma.